Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients

Zhu, Dedong; Yuan, Denggao; Wang, Zhe; Chen, Sihan

doi:10.1097/md.0000000000015682

Cited by 10 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(2) DEBs are able to release antitumor medicine continuously and slowly in tumor tissues, which can significantly increase the drug concentration in tumor tissues and control recurrence. (3) Microspheres firmly combined with antitumor drugs can dramatically decrease the amount of medicine released into the body circulation, thus decreasing the toxic side effects of drugs [ 12 , 13 ]. Currently, DEB-TACE is widely applied in primary liver cancer with satisfactory results [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Drug-Eluting Bead Transarterial Chemoembolization in the Treatment of Colorectal Cancer Liver Metastasis

Chen

Yang

Jiao

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

We aimed to investigate the efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of colorectal cancer liver metastasis. A total of 120 patients with colorectal cancer liver metastasis were divided into the TACE group (receiving TACE treatment, n = 60) and the DEB-TACE group (receiving DEB-TACE treatment, n = 60). At 1 month after treatment, the objective response rate (ORR) in the TACE group and DEB-TACE group were 65.0% (39/60) and 78.3% (47/60), respectively, and the disease control rate (DCR) was 78.3% (47/60) and 85.0% (51/60), respectively. Three months later, the ORRs in TACE and DEB-TACE groups were 63.3% (38/60) and 75.0% (45/60), and the DCRs were 76.7% (46/60) and 81.7% (49/60). We showed that the 1-year overall survival (OS) in TACE and DEB-TACE groups were 100% (60/60) and 88.3% (53/60), respectively, and the 2-year OS were 78.3% (47/60) and 61.7% (37/60). Further analysis indicated that the OS in the DEB-TACE group was significantly longer than that in the TACE group (P = 0.045). DEB-TACE is effective, safe, and feasible in the treatment of colorectal cancer liver metastasis, which can effectively improve the survival of patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of Drug-Eluting Bead Transarterial Chemoembolization in the Treatment of Colorectal Cancer Liver Metastasis

Chen

Yang

Jiao

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

show abstract

“…Overall, these results were comparable to those reported in other literature on the treatment of unresectable HCC with DEB-TACE. 11 , 12 However, they were significantly better than previously reported survival of c-TACE in the treatment of advanced HCC. 13 , 14 The primary objective of this study was to identify factors that affect the prognosis of DEB-TACE in the treatment of unresectable HCC and to establish a simple, practical, and reliable prognostic scoring system to predict the efficacy and survival benefit of DEB-TACE in HCC patients.…”

Section: Discussionmentioning

confidence: 76%

A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with DEB-TACE

Jiang,

Lu,

Dai

et al. 2024

JHC

View full text Add to dashboard Cite

“…Ahmed et al[ 43 ] found that RFA can increase the permeability of capillaries by dilating the nutritional blood vessels of the tumor, which is conducive to the residual chemotherapy drugs acting on tumor tissue. Zhu et al[ 44 ] found that the combined application of DEB-TACE and RFA improved the efficacy and survival time. However, combined treatment will increase the cost and prolong the hospital stay.…”

Section: Discussionmentioning

confidence: 99%

Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma

Zhang¹,

Zhang²,

Fan³

et al. 2020

WJGS

View full text Add to dashboard Cite

BACKGROUND Drug-eluting beads transarterial chemoem-bolization (DEB-TACE) has the advantages of slow and steady release, high local concentration, and low incidence of adverse drug reactions compared to the traditional TACE. DEB-TACE combined with sequentially ultrasound-guided radiofrequency ablation (RFA) therapy has strong anti-cancer effects and little side effects, but there are fewer related long-term studies until now. AIM To explore the outcome of DEB-TACE sequentially combined with RFA for patients with primary hepatocellular carcinoma (HCC). METHODS Seventy-six patients with primary HCC who underwent DEB-TACE sequentially combined with RFA were recruited. Forty patients with untreated HCC were included in Group A, and 36 patients with recurrent HCC were included in Group B. In addition, 40 patients with untreated HCC who were treated with hepatectomy were included in Group C. The serological examination, preoperative magnetic resonance imaging examination, and post-treatment computed tomography enhanced examination were performed for all patients. The efficacy was graded as complete remission (CR), partial remission (PR), stable disease and progressive disease at the 3 rd , 6 th , and 9 th . All patients were followed up for 3 years and their overall survival (OS), disease-free survival (DFS) were assessed. RESULTS The efficacy of Group A and Group C was similar ( P > 0.05), but the alanine aminotransferase, aspartate aminotransferase and total bilirubin of Group A were lower than those of Group C (all P < 0.05). The proportions of CR (32.5%), PR (37.5%) were slightly higher than Group A (CR: 27.5%, PR: 35%), but the difference was not statistically significant ( χ 2 = 0.701, P = 0.873). No operational-related deaths occurred in Group A and Group C. The OS (97.5%, 84.7%, and 66.1%) and the DFS (75.0%, 51.7%, and 35.4%) of Group A at the 1 st , 2 nd , and 3 rd year after treatment were similar with those of Group C (OS: 90.0%, 79.7%, and 63.8%; DFS: 80.0%, 59.7%, and 48.6%; P > 0.05). The OS rates in Group A and Group B (90%, 82.3%, and 66.4%) were similar ( P > 0.05). The DFS rates in Group B (50%, 31.6%, and 17.2%) were lower than that of Group A ( P = 0.013). CONCLUSION The efficacy of DEA-TACE combined with RFA for untreated HCC is similar with hepatectomy. Patients with recurrent HCC could get a longer survival time through the combined treatment.

show abstract

Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients

Cited by 10 publications

References 24 publications

Efficacy of Drug-Eluting Bead Transarterial Chemoembolization in the Treatment of Colorectal Cancer Liver Metastasis

Efficacy of Drug-Eluting Bead Transarterial Chemoembolization in the Treatment of Colorectal Cancer Liver Metastasis

A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with DEB-TACE

Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma

Contact Info

Product

Resources

About